Basel Medical Group Ltd filed a Form 6-K with the SEC on October 29, 2026, disclosing that holders of 6,000,000 Common Warrants exercised those warrants using the zero cash exercise option, resulting in the issuance of 6,000,000 new Ordinary Shares with no new proceeds raised.

Key Highlights

  • 6,000,000 warrants exercised: According to the filing, warrant holders exercised an aggregate of 6,000,000 Common Warrants, each using the zero cash exercise option.
  • No new proceeds: The filing states that no new proceeds were raised from the warrant exercises.
  • 6,000,000 new Ordinary Shares issued: The company disclosed it issued a total of 6,000,000 new Ordinary Shares pursuant to the warrant exercises.
  • Total shares outstanding: As of October 29, 2026, the company reported 13,582,111 Ordinary Shares issued and outstanding.
  • Originating offering closed October 9, 2026: The filing notes the related offering of 6,000,000 units, each consisting of one Ordinary Share and one Common Warrant, was closed on October 9, 2026.

Basel Medical Group Discloses Zero-Cash Warrant Exercises Following October 2026 Unit Offering

Basel Medical Group Ltd (NASDAQ:BMGL), a British Virgin Islands business company headquartered in Singapore, reported in its October 2026 Form 6-K that all 6,000,000 Common Warrants issued as part of a recent unit offering were exercised by warrant holders using the zero cash exercise option. The company noted that the offering of 6,000,000 units had closed on October 9, 2026, with each unit consisting of one Ordinary Share and one Common Warrant to purchase one additional Ordinary Share.

According to the filing, the warrant holders submitted exercise notices covering the full 6,000,000 Common Warrants. Because the zero cash exercise option was selected for all exercises, the company disclosed that no new proceeds were raised as a result. The filing does not elaborate on the terms of the zero cash exercise option beyond this characterization.

As a direct result of the warrant exercises, the company reported issuing 6,000,000 new Ordinary Shares, each with no par value. The filing states that as of October 29, 2026, Basel Medical Group Ltd had a total of 13,582,111 Ordinary Shares issued and outstanding. The report was signed by Alton Chun How Neo, Interim Chief Financial Officer, on October 29, 2026.

What Was Disclosed

The Form 6-K discloses that all 6,000,000 Common Warrants from a unit offering closed October 9, 2026, were exercised using the zero cash exercise option, resulting in 6,000,000 new Ordinary Shares issued and a total of 13,582,111 shares outstanding as of October 29, 2026.